MedImmune, which already markets Synagis to prevent respiratory syncytial virus in high-risk infants, made another investment in the RSV space by signing a $112 million deal to develop small-molecule compounds discovered by Australian company Biota Holdings Ltd. (BioWorld Today)
In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)
In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)
ViroPharma Inc. is raising $150.7 million through a public offering to support business development activities and general corporate purposes, as well as to pay off a portion of the company's debt. (BioWorld Today)
